BlogFile: Targacept, Inc. (TRGT)

May 13, 2007 · Filed Under blogfile, targacept · Comment 

BioHealth Investor.com

COMPANY BlogFILE
updated: May 13, 2007

TARGACEPT, Inc.

200 East First Street, Suite 300
Winston-Salem, NC 27101-4165
USA
Phone: (336) 480-2100
Fax: (336) 480-2107
www.targacept.com

Investor/Public Relations
Alan Musso
Vice President and Chief Financial Officer
(336) 480-2186
(336) 480-2103
alan.musso@targacept.com

COMPANY DESCRIPTION

Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs.NNrs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

BUSINESS INFORMATION

Public company
Ticker: TRGT
Market: NASDAQ
Industry: Biotechnology

LATEST BLOG COMMENTARY

Tiny Targacept Experiences Unusual Volume Surge
SeekingAlpha
April 18, 2007

Targacept: Late Day Volume Surge Deserves Attention
BioHealth Investor
April 17, 2007

Wednesday Pre-market Notes By Stock Ticker
SeekingAlpha
April 12, 2007

Barron’s Alzheimer’s Article Only Scratches the Surface
24/7 Wall St.
March 31, 2007

Friday’s Top Biotech and Medical Stocks
BioHealth Investor
November 04, 2007

Thursday’s Top Biotech and Medical Stocks
BioHealth Investor
November 02, 2006

Source: BioHealth Investor.com

___________________

BlogFile: Dendreon Corporation (DNDN)

May 13, 2007 · Filed Under blogfile, dendreon · 2 Comments 

BioHealth Investor.com

COMPANY BlogFILE
updated: May 15, 2007

DENDREON CORPORATION

3005 First Avenue
Seattle, WA 98121
Phone: (206) 256-4545
Fax: (206) 256-0571
www.dendreon.com

Investor/Public Relations
(206) 829-1500
ir@dendreon.com

COMPANY DESCRIPTION

Dendreon Corporation is a Seattle-based biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Through innovative science and technology, is striving to develop and commercialize products that address unmet medical needs, improve survival and have a favorable safety profile.

BUSINESS INFORMATION

Public company
Ticker: DNDN
Market: NASDAQ
Industry: Biotechnology

LATEST BLOG COMMENTARY

Dendreon, the Day That Could Have Been and What to Expect Now
24/7 Wall St.
May 15, 2007

Why Did the FDA Decide to Flunk Dendreon’s Provenge?
SeekingAlpha
May 14, 2007

Dendreon – Is Provenge Snake Oil or Cure?
The Disciplined Investor
May 12, 2007

DNDN… is it Over?
Echo To All
May 12, 2007

Rantasorous Rx
Health Business Blog
May 11, 2007

Comments From Dendreon’s Conference Call (May 10, 2007)
24/7 Wall St.
May 10, 2007

Dendreon Gets Complete Response Letter
Eye On FDA
May 09, 2007

Dendreon Nailed by FDA
24/7 Wall St.
May 09, 2007

Dendreon: The Short Story
SeekingAlpha
May 09, 2007

Dendreon: The Next Genentech/Amgen?
SeekingAlpha
May 04, 2007

Source: BioHealth Investor.com

____________________

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed